<![CDATA[FDA Issues Complete Response Letter for Orviglance in Liver Imaging]]>
Read the full articleYou might also wanna read
Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
Conditions : Hepatocellular Carcinoma (HCC); Liver Cancer, Adult Interventions : Procedure: Parenchymal Blood Volume (PBV) Imaging; Drug: Ni
Polarization-sensitive optical coherence tomography enables noninvasive whole-donor-liver viability assessment
Human liver transplantation is constrained by a critical shortage of viable donor livers. In response to this shortage, marginal livers from
scim.ag·11d agoPolarization-sensitive optical coherence tomography enables noninvasive whole-donor-liver viability assessment
Human liver transplantation is constrained by a critical shortage of viable donor livers. In response to this shortage, marginal livers from
scim.ag·11d agoRetinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
Conditions : Transthyretin Amyloid Cardiomyopathy Sponsors : AstraZeneca Not yet recruiting
Imaging in Semaglutide Study
Conditions : Type 2 Diabetes; BMI Greater Than 30 Interventions : Radiation: 31P-MRS and MRI Sponsors : The Cleveland Clinic Not yet recruit
A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
Conditions : Solid Tumor Interventions : Drug: F18 FBPA Injection Sponsors : Heron Neutron Medical Corp. Recruiting
HLB liver cancer drug hits FDA setback again over manufacturing issues
HLB's hopes of bringing its liver cancer treatment to the US market have suffered another blow after the US Food and Drug Administration iss
Comments
Sign in to join the conversation.
No comments yet. Be the first.